|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
654303540[A15254271]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2008.05.01)(ÇöÀç¾à°¡)
\173 ¿ø/1g(2005.12.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ƯÀÌÇÑ ÇâÀÌ ÀÖ´Â ÁÖȲ»öÀÇ °ú¸³Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
(ĸ½¶Á¦)(½Ã·´Á¦)(°ú¸³Á¦) ¡Û À¯È¿±ÕÁ¾ Æó·Å¿¬¼â±¸±Õ, ÀÎÇ÷翣ÀÚ±Õ, Æ÷µµ±¸±Õ, ½ºÆ®·¾ÅäÄÛÄí½º ÇÇ¿À°Ô³×½º(±×·ìA-º£Å¸¿ëÇ÷¼º), ´ëÀå±Õ, ÇÁ·ÎÅ׿콺 ¹Ì¶óºô¸®½º, Ŭ·¹ºê½Ã¿¤¶ó, ÀÓ±Õ ¡Û ÀûÀÀÁõ - ÁßÀÌ¿° - Æó·Å, ÀÎÈĵο°, Æíµµ¿°, ±â°üÁö¿° - ½Å¿ì½Å¿°, ¹æ±¤¿°, ÀÓ±Õ¼º ¿äµµ¿° - ºÎ½º·³, ¿ËÁ¾, ¸ð³¶¿°, ¿¬Á¶Á÷¿°, °¨¿°¼º Á×Á¾, ÇÇÇϳó¾ç, »ýÀμÕ, â»ó°¨¿°
|
| ¾à¹°À½½Ä°£ »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:125201AGN ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] (ĸ½¶Á¦)(½Ã·´Á¦)(°ú¸³Á¦)
¡Û ¼ºÀÎ : ¼¼ÆÄŬ·¯·Î¼ 1ȸ 250mg(¿ª°¡)À» 8½Ã°£¸¶´Ù °æ±¸ Åõ¿©ÇÑ´Ù. ÁßÁõ°¨¿°Áõ(Æó·Å µî)°ú °¨¼ö¼ºÀÌ ³·Àº °¨¿°ÁõÀÇ °æ¿ì 2¹è·Î Áõ·® Åõ¿©ÇÒ ¼ö ÀÖ´Ù. ±Þ¼º ÀÓ±Õ¼º ¿äµµ¿°ÀÇ °æ¿ì ÀÌ ¾à 3g°ú ÇÁ·Îº£³×½Ãµå 1gÀ» ´Üȸ º´¿ë Åõ¾àÇÑ´Ù.
¡Û ¼Ò¾Æ : 1ÀÏ Ã¼Áß Kg´ç 20mg(¿ª°¡)À» 8½Ã°£¸¶´Ù ºÐÇÒ Åõ¿©ÇÑ´Ù. ÁßÁõ°¨¿°Áõ, ÁßÀÌ¿° ¹× °¨¼ö¼ºÀÌ ³·Àº °¨¿°ÀÇ °æ¿ì¿¡´Â 1ÀÏ Ã¼Áß Kg´ç 40mg(¿ª°¡)À» Åõ¿©ÇÒ ¼ö ÀÖÀ¸¸ç ÃÖ´ë¿ë·®Àº 1ÀÏ 1g(¿ª°¡)ÀÌ´Ù.
¡Û ½Å±â´É ¼Õ»ó ȯÀÚ : ¿ë·® º¯È ¾øÀÌ Åõ¿©ÇÒ ¼ö ÀÖ´Ù. º£Å¸¿ëÇ÷¼º ¿¬¼â±¸±Õ°¨¿°ÀÇ Ä¡·á´Â Àû¾îµµ 10Àϰ£ Åõ¿©ÇØ¾ß ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ ÀÇÇÏ¿© ¼ïÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ÀÌ ¾à ¶Ç´Â ¼¼ÆÈ·Î½ºÆ÷¸°°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) Æä´Ï½Ç¸°°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) º»ÀÎ ¶Ç´Â ºÎ¸ðÇüÁ¦°¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±â Áõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀΠȯÀÚ
3) ÁßÁõÀÇ ½ÅÀå¾Ö ȯÀÚ
4) °æ±¸¼·Ãë°¡ ºÒ·®ÇÑ È¯ÀÚ ¶Ç´Â ºñ°æ±¸¿µ¾ç ȯÀÚ, °í·ÉÀÚ, Àü½Å»óŰ¡ ³ª»Û ȯÀÚ(ºñŸ¹Î K °áÇÌÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÑ´Ù.)
5) À§Àå°üÁúȯÀÇ º´·ÂÀÌ Àִ ȯÀÚ(ƯÈ÷ ´ëÀå¿°)
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼ï : µå¹°°Ô ¼ïÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) °ú¹Î¹ÝÀÀ : ¾Æ³ªÇʶô½Ã¾ç Áõ»ó(Àü½ÅÈ«Á¶, ºÎÁ¾, È£Èí°ï¶õ, ¸Æ°üºÎÁ¾, °¨°¢ÀÌ»ó, ½Ç½Å, °íÇ÷¾Ð, Ç÷°üÈ®Àå), ¹ßÁø, µÎµå·¯±â, È«¹Ý, °¡·Á¿ò, ¹ß¿, ¸²ÇÁÀý Á¾Ã¢, °üÀýÅë, Ç÷ûº´¾ç ¹ÝÀÀ(¹ßÁø, ´ÙÇüÈ«¹Ý, °üÀý¿°, °üÀýÅë, ¹ß¿Àº ¼ö¹ÝµÇ°Å³ª ¼ö¹ÝµÇÁö ¾ÊÀ½.) µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ Áõ»ó, ¡ÈĵéÀº Åõ¿©¸¦ ½ÃÀÛÇÑ ÈÄ ¸çÄ¥ À̳»¿¡ ³ªÅ¸³ª¼, Åõ¿© Á¾·á ÈÄ ¸çÄ¥ À̳»¿¡ ¼Ò½ÇµÈ´Ù. Ç×È÷½ºÅ¸¹Î ¹× ÄÚ¸£Æ¼ÄÚÀ̵å´Â ȸº¹À» µµ¿ÍÁØ´Ù.
3) ÇǺΠ: ½ºÆ¼ºì½º-Á¸½¼ÁõÈıº, µ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
4) Ç÷¾×°è : ¶§¶§·Î ¹«°ú¸³±¸Áõ, °ú¸³±¸ °¨¼Ò ¶ÇÇÑ µå¹°°Ô ¹üÇ÷±¸ °¨¼Ò, ºóÇ÷, Ç÷¼ÒÆÇ °¨¼Ò, È£»ê±¸ Áõ°¡, ¸²ÇÁ±¸ Áõ°¡, ¹éÇ÷±¸ °¨¼Ò, Àç»ýºÒ·®¼ººóÇ÷, ¿ëÇ÷¼º ºóÇ÷, °¡¿ªÀû È£Áß±¸ °¨¼Ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸?·Î ÃæºÐÈ÷ °üÂûÇÏ¿© ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
5) °£Àå : µå¹°°Ô ÀϽÃÀûÀÎ °£¿°, Ȳ´Þ, ¶§¶§·Î AST, ALT, ALPÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
6) ½ÅÀå : °¡¿ªÀû °£Áú¼º ½Å¿°, µå¹°°Ô BUN »ó½Â, Ç÷ûũ·¹¾ÆÆ¼´Ñ »ó½Â, ±Þ¼º ½ÅºÎÀü µîÀÇ ÁßÁõÀÇ ½ÅÀå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î °Ë»ç¸¦ ½Ç½ÃÇÏ´Â µî ÃæºÐÈ÷ °üÂûÇϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ¸î¸î ¼¼ÆÈ·Î½ºÆ÷¸°°è Ç×»ý¹°ÁúÀº ƯÈ÷ ½ÅÀå¾Ö ȯÀÚ¿¡°Ô ¿ë·®À» °¨·®ÇÏÁö ¾Ê°í Åõ¿© ½Ã ¹ßÀÛÀÌ ¾ß±âµÉ ¼ö ÀÖ´Ù. ¹ßÀÛÀÌ ¾à¹°Ä¡·á¿Í °ü·ÃÀÌ ÀÖ´Ù¸é ¾à¹°Ä¡·á¸¦ Áß´ÜÇØ¾ß Çϰí ÀÓ»óÀûÀ¸·Î ÇÊ¿äÇÒ °æ¿ì Ç×°æ·ÃÁ¦¸¦ Åõ¿©ÇÑ´Ù.
7) ¼Òȱâ°è : µå¹°°Ô À§¸·¼º´ëÀå¿° µîÀÇ Ç÷º¯À» ¼ö¹ÝÇÏ´Â ÁßÁõÀÇ ´ëÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. º¹Åë, ºó¹øÇÑ ¼³»ç°¡ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ¶ÇÇÑ ¶§¶§·Î ±¸¿ª, ±¸Åä, ¼³»ç, º¹Åë, À§ºÎºÒÄè°¨, °¡½¿¾²¸², ½Ä¿åºÎÁø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) È£Èí±â°è : ´Ù¸¥ ¼¼Æè°è Ç×»ý¹°Áú Åõ¿© ½Ã µå¹°°Ô ¹ß¿, ±âħ, È£Èí°ï¶õ, ÈäºÎ X¼± ÀÌ»ó, È£»ê±¸ Áõ°¡ µîÀ» ¼ö¹ÝÇÏ´Â °£Áú¼º Æó·Å, È£»ê±¸¼º ÆóħÀ± µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÄÚ¸£Æ¼ÄÚÀ̵å Åõ¿© µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
9) ÁßÃ߽Űæ°è : µå¹°°Ô °¡¿ªÀûÀÎ ±â´ÉÇ×Áø, ÃÊÁ¶, ºÒ¾È, °ú´Ù±ÙÀ° ±äÀåÁõ, ½Å°æ°ú¹Î, ºÒ¸é, Âø¶õ, ¾îÁö·¯¿ò, ȯ°¢, Á¹À½ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
10) ±Õ±³´ëÁõ : µå¹°°Ô ±¸³»¿°, ĵð´ÙÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ºñŸ¹Î°áÇÌÁõ : µå¹°°Ô ºñŸ¹Î K °áÇÌÁõ»ó(ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ, ÃâÇ÷°æÇâ µî), ºñŸ¹Î B±º ?ÇÌÁõ»ó(¼³¿°, ±¸³»¿°, ½Ä¿åºÎÁø, ½Å°æ¿° µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù
12) ±âŸ : µå¹°°Ô µÎÅë, »ý½Ä±â °¡·Á¿ò, Áú¿°, Áú ¸ð´Ò¸®¾ÆÁõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
13) ¼¹æÁ¤ÀÇ ÀÓ»ó½ÃÇè°á°ú Ãß°¡µÈ ÀÌ»ó¹ÝÀÀÀº ´ÙÀ½°ú °°´Ù.
ºÒÀÇÀÇ »óó, ½Ä¿åºÎÁø, ºÒ¾È, °üÀýÅë, õ½Ä, ±â°üÁö¿°, ÈäÅë, ¿ÀÇÑ, ¿ïÇ÷¼º½ÉºÎÀü, °á¸·¿°, º¯ºñ, ¾îÁö·¯¿ò, ¿ù°æÅë, ¼ÒȺҷ®, ¹è´¢°ï¶õ, ±ÍÀÇ ÅëÁõ, ºÎÁ¾, ¹ß¿, º¹ºÎÆØ¸¸°¨, À§¿°, °¨¿°, ºÒ¸éÁõ, ÁúºÐºñ¹°, ¹ßÁø, ±ÇÅÂ, ¿ù°æºÒ¼ø, ±ÙÀ°Åë, ±¸¿ª, ±¸Åä, ¸ñÀÇ ÅëÁõ, ½Å°æÁú, ¾ß´¢Áõ, ÁßÀÌ¿°, ÅëÁõ, ½É°èÇ×Áø, È£Èí°ï¶õ, ºÎºñµ¿¿°, Á¹À½, ¶¡, ¶³¸², µÎµå·¯±â
|
| »óÈ£ÀÛ¿ë |
1) ÇÁ·Îº£³×½Ãµå¿Í º´¿ëÅõ¿© ½Ã ÀÌ ¾àÀÇ ¼¼´¢°ü ¹è¼³ ¼Óµµ°¡ °¨¼ÒµÇ¾î Ç÷Á߳󵵸¦ Áö¼Ó ½Ãų ¼ö ÀÖ´Ù.
2) ¸¶±×³×½· È÷µå·Ï»çÀÌµå ¶Ç´Â ¾Ë·ç¹Ì³ª Æ®¸®È÷µå·¹ÀÌÆ®¸¦ Æ÷ÇÔÇÑ Á¦»êÁ¦¸¦ Ç×»ý¹°Áú Åõ¿©ÀÇ 1½Ã°£ ³»¿¡ º¹¿ëÇϸé ÀÌ ¾àÀÇ Èí¼ö°¡ °¨¼ÒµÈ´Ù. H2 ¾ïÁ¦Á¦´Â ÀÌ ¾àÀÇ Èí¼ö ¼Óµµ ¹× Èí¼ö·®¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê´Â´Ù(¼¹æÁ¤¿¡ ÇÑÇÔ.).
3) ½Åµ¶¼ºÀÌ ÀÖ´Â Ç×»ý¹°Áú ¶Ç´Â ÀÌ´¢Á¦(Ǫ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)¸¦ º´¿ëÅõ¿© ½Ã ½ÅÀå¾Ö°¡ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
4) INR(±¹Á¦Á¤»óȺñÀ²)ÀÇ º¯È : ÀÌ ¾àÀ» Æ÷ÇÔÇÑ Ç×»ý¹°ÁúÀ» Ç×ÀÀ°íÁ¦¿Í µ¿½Ã¿¡ Åõ¿© ¹ÞÀº ȯÀÚ¿¡¼ Ç×ÀÀ°í Ȱ¼ºÀÇ Áõ°¡°¡ º¸°íµÇ¾ú´Ù. °¨¿°¼ºÁúȯ(±×¸®°í ¿°Áõ¼º °úÁ¤À» µ¿¹ÝÇÑ), ȯÀÚÀÇ ¿¬·É°ú ÀϹÝÀûÀÎ »óÅ´ À§Çè¿ä¼Ò°¡ µÈ´Ù. ºñ·Ï ÀÌ ¾à°ú ¿ÍÆÄ¸°ÀÇ »óÈ£ÀÛ¿ëÀÌ ÀÓ»ó½ÃÇèÀ» ÅëÇØ ¹àÇôÁöÁö ¾Ê¾ÒÁö¸¸ INR ¸ð´ÏÅ͸µÀ» ½Ç½ÃÇÏ¿©¾ß Çϰí, ÇÊ¿äÇÑ °æ¿ì °æ±¸¿ë Ç×ÀÀ°íÁ¦ÀÇ ¿ë·®À» ÀûÀýÈ÷ Á¶ÀýÇÑ´Ù. Ç×»ý¹°ÁúÀÇ ÀϺΠÁ¾·ùµé, ƯÈ÷ Ç÷ç¿À·ÎÄû³î·Ð, ¸¶Å©·Î¶óÀ̵å, »çÀÌŬ¸°, ÄÚÆ®¸®¸ñ»çÁ¹°ú ÀϺΠ¼¼ÆÈ·Î½ºÆ÷¸°ÀÇ °æ¿ì´Â ´õ ½ÉÇÏ´Ù.
5) °æ±¸ ÇÇÀÓ¾à°ú º´¿ëÅõ¿© ½Ã ÇÇÀÓÀÇ È¿°ú°¡ °¨¼Ò½Ãų ¼ö ÀÖÀ¸¹Ç·Î ´Ù¸¥ ÇÇÀÓ¹ýÀ» Ãß°¡·Î »ç¿ëÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
6) Á¤±Õ¼º Ç×»ý¹°Áú(Ŭ·Î¶÷Æä´ÏÄÝ, ¿¡¸®½º·Î¸¶À̽Å, Åׯ®¶ó»çÀÌŬ¸° µî)°ú º´¿ëÅõ¿© ½Ã ÀÌ ¾àÀÇ »ì±ÕÀÛ¿ëÀ» °¨¼Ò½Ãų ¼ö ÀÖ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ´ëÇ¥ÄÚµå |
8806543035408 |
| BIT ¾àÈ¿ºÐ·ù |
2¼¼´ë ¼¼ÆÈ·Î½ºÆ÷¸°°è (Cephalosporins; Second Generation)
|
| º¹ÁöºÎºÐ·ùÄÚµå |
618 (ÁÖ·Î ±×¶÷¾ç¼º, À½¼º±Õ¿¡ ÀÛ¿ëÇÏ´Â °Í )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
¼¼ÆÄ·º½º°ú¸³(¼¼ÆÄŬ·¯)/ A15254271
Á¦Ç°±Ô°Ý: /Á¦Ç°¼ö·®: /Á¦Çü:
Æû¸ñ±âÁØÄÚµå: 200501844 /´ëÇ¥ÄÚµå: 8806543035408/Ç¥ÁØÄÚµå: 8806543035408
±¸¹ÙÄÚµå: -/ºñ°í:½Ä¾àûÇã°¡ ÃëÇÏ Ç°¸ñ(20070111)
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cefaclor¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Cefaclor, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that cefaclor interferes with an autolysin inhibitor.
|
| Pharmacology |
Cefaclor¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cefaclor is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A ©¬-hemolytic streptococci). Gram-negative aerobes - Escherichia coli, Haemophilus influenzae (including ©¬-lactamase-producing ampicillin-resistant strains), Klebsiella sp, and Proteus mirabilis.
|
| Absorption |
Cefaclor¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed after oral administration, independent of food intake.
|
| Pharmacokinetics |
CefaclorÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ : Àß Èí¼öµÇ¸ç »ê¿¡¼µµ ¾ÈÁ¤ÇÏ´Ù.
- ºÐÆ÷ : ÅÂ¹Ý Åë°ú, À¯Áó ºÐºñ
- ´Ü¹é°áÇÕ : 25%
- ´ë»ç : ÀϺΰ¡ ´ë»çµÈ´Ù.
- ¹Ý°¨±â : 0.5-1 ½Ã°£ (½ÅÀå¾Ö½Ã ¿¬Àå)
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ :
- ݼ¿Á¦ : 60ºÐ
- Çöʾ×Á¦ : 45ºÐ
- ¼Ò½Ç : 80%°¡ ¹Ìº¯Èü·Î ½Å¹è¼³
|
| Toxicity |
Cefaclor¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.
|
| Drug Interactions |
Cefaclor¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Probenecid Probenecid increases the antibiotic's level
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cefaclor¿¡ ´ëÇÑ Description Á¤º¸ Semisynthetic, broad-spectrum antibiotic derivative of cephalexin. [PubChem]
|
| Dosage Form |
Cefaclor¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralPowder OralPowder, for solution OralPowder, for suspension OralSuspension Oral
|
| Drug Category |
Cefaclor¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsCephalosporins
|
| Smiles String Canonical |
Cefaclor¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(C(=O)NC1C2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
|
| Smiles String Isomeric |
Cefaclor¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N[C@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
|
| InChI Identifier |
Cefaclor¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9?,10-,14-/m1/s1/f/h18,22H
|
| Chemical IUPAC Name |
Cefaclor¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6R,7R)-7-[(2-amino-2-phenylacetyl)amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-10-22
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|